ATE177321T1 - Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper - Google Patents
Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörperInfo
- Publication number
- ATE177321T1 ATE177321T1 AT90908737T AT90908737T ATE177321T1 AT E177321 T1 ATE177321 T1 AT E177321T1 AT 90908737 T AT90908737 T AT 90908737T AT 90908737 T AT90908737 T AT 90908737T AT E177321 T1 ATE177321 T1 AT E177321T1
- Authority
- AT
- Austria
- Prior art keywords
- agent
- antibody
- antibodies
- soluble substrate
- targeting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Non-Portable Lighting Devices Or Systems Thereof (AREA)
- Led Device Packages (AREA)
- Fastening Of Light Sources Or Lamp Holders (AREA)
- Arrangement Of Elements, Cooling, Sealing, Or The Like Of Lighting Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1989/005441 WO1991008770A1 (en) | 1989-12-11 | 1989-12-11 | Method for antibody targeting of diagnostic or therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE177321T1 true ATE177321T1 (de) | 1999-03-15 |
Family
ID=22215397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT90908737T ATE177321T1 (de) | 1989-12-11 | 1989-12-11 | Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0505357B1 (de) |
| JP (1) | JP3032287B2 (de) |
| KR (1) | KR100236375B1 (de) |
| AT (1) | ATE177321T1 (de) |
| AU (1) | AU649952B2 (de) |
| DE (1) | DE68928946T2 (de) |
| WO (1) | WO1991008770A1 (de) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5773435A (en) * | 1987-08-04 | 1998-06-30 | Bristol-Myers Squibb Company | Prodrugs for β-lactamase and uses thereof |
| US6610299B1 (en) | 1989-10-19 | 2003-08-26 | Aventis Pharma Deutschland Gmbh | Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates |
| DE4106389A1 (de) * | 1991-02-28 | 1992-09-03 | Behringwerke Ag | Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung |
| US7241595B2 (en) | 1989-10-20 | 2007-07-10 | Sanofi-Aventis Pharma Deutschland Gmbh | Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates |
| US5965106A (en) * | 1992-03-04 | 1999-10-12 | Perimmune Holdings, Inc. | In vivo binding pair pretargeting |
| US5578289A (en) * | 1992-03-04 | 1996-11-26 | Akzo N.V. | In vivo binding pair pretargeting |
| DE4233152A1 (de) | 1992-10-02 | 1994-04-07 | Behringwerke Ag | Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung |
| US7011812B1 (en) | 1996-05-03 | 2006-03-14 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
| JPH1160499A (ja) * | 1997-08-22 | 1999-03-02 | Hiroshi Maeda | 抗腫瘍剤 |
| US6919076B1 (en) | 1998-01-20 | 2005-07-19 | Pericor Science, Inc. | Conjugates of agents and transglutaminase substrate linking molecules |
| US6361774B1 (en) * | 1999-09-17 | 2002-03-26 | Immunomedics, Inc. | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug |
| US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| PT1260215E (pt) | 2000-03-01 | 2009-09-03 | Eisai R&D Man Co Ltd | Comprimido de desintegração rápida que contém poli(álcool vinílico) |
| WO2001097855A2 (en) | 2000-06-20 | 2001-12-27 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
| AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| EP4793360A2 (de) | 2006-03-31 | 2026-08-19 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern |
| JP5144499B2 (ja) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
| EP3127921A1 (de) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstition in cdr |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| AU2011289579B2 (en) | 2010-08-10 | 2016-11-17 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| CN105859889B (zh) | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| GB201106742D0 (en) | 2011-04-20 | 2011-06-01 | Spheritech Ltd | Cross-linked poly-e-lysine |
| CA2925256C (en) | 2013-09-27 | 2023-08-15 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| CA2946064C (en) | 2014-02-21 | 2023-09-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Glycotargeting therapeutics |
| TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定ｆｖｉｉｉ的反應性之方法 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| US20200270363A1 (en) | 2015-12-25 | 2020-08-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
| SG11201803989WA (en) | 2015-12-28 | 2018-06-28 | Chugai Pharmaceutical Co Ltd | Method for promoting efficiency of purification of fc region-containing polypeptide |
| AU2017255077B2 (en) | 2016-04-28 | 2024-05-16 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
| CA3027018A1 (en) | 2016-07-29 | 2018-02-01 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity |
| US11352438B2 (en) | 2016-09-06 | 2022-06-07 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X |
| JP7209298B2 (ja) | 2017-03-31 | 2023-01-20 | 公立大学法人奈良県立医科大学 | 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物 |
| EP3638296A1 (de) | 2017-06-16 | 2020-04-22 | The University Of Chicago | Zusammensetzungen und verfahren zur herbeiführung einer immuntoleranz |
| CA3071236A1 (en) | 2017-09-29 | 2019-04-04 | Chugai Seiyaku Kabushiki Kaisha | Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient |
| KR20260090008A (ko) | 2017-11-01 | 2026-06-16 | 추가이 세이야쿠 가부시키가이샤 | 생물 활성이 저하된 항체 배리언트 및 아이소폼 |
| EP3790577A4 (de) | 2018-05-09 | 2022-04-27 | The University of Chicago | Zusammensetzungen und verfahren im zusammenhang mit immuntoleranz |
| MX2021000644A (es) | 2018-07-18 | 2021-08-19 | Manzanita Pharmaceuticals Inc | Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2523445A1 (fr) * | 1982-03-17 | 1983-09-23 | Sanofi Sa | Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues |
| US4472509A (en) * | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| CA1282069C (en) * | 1985-09-12 | 1991-03-26 | Damon L. Meyer | Antibody complexes of hapten-modified diagnostic or therapeutic agents |
| US4699784A (en) * | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| GB8705477D0 (en) * | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| NZ225599A (en) * | 1987-08-04 | 1991-09-25 | Bristol Myers Co | Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells |
| GB8809616D0 (en) | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
| CA2025899A1 (en) * | 1989-01-23 | 1990-07-24 | Reinhard Bredehorst | Site specific in-vivo activation of therapeutic drugs |
| AU633867B2 (en) * | 1989-02-02 | 1993-02-11 | Eli Lilly And Company | Delivery of cytotoxic agents |
| DE3935016A1 (de) * | 1989-10-20 | 1991-04-25 | Behringwerke Ag | Glycosyl-etoposid-prodrugs, verfahren zu ihrer herstellung und ihre anwendung in kombination mit funktionalisiertem tumorspezifischen enzym-konjugaten |
-
1989
- 1989-12-11 EP EP90908737A patent/EP0505357B1/de not_active Expired - Lifetime
- 1989-12-11 WO PCT/US1989/005441 patent/WO1991008770A1/en not_active Ceased
- 1989-12-11 AU AU56736/90A patent/AU649952B2/en not_active Ceased
- 1989-12-11 KR KR1019910700828A patent/KR100236375B1/ko not_active Expired - Fee Related
- 1989-12-11 DE DE68928946T patent/DE68928946T2/de not_active Expired - Fee Related
- 1989-12-11 JP JP02508109A patent/JP3032287B2/ja not_active Expired - Fee Related
- 1989-12-11 AT AT90908737T patent/ATE177321T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE68928946D1 (de) | 1999-04-15 |
| EP0505357B1 (de) | 1999-03-10 |
| JP3032287B2 (ja) | 2000-04-10 |
| KR920702819A (ko) | 1992-10-28 |
| AU649952B2 (en) | 1994-06-09 |
| EP0505357A4 (de) | 1994-03-16 |
| AU5673690A (en) | 1991-07-18 |
| DE68928946T2 (de) | 1999-10-21 |
| EP0505357A1 (de) | 1992-09-30 |
| KR100236375B1 (ko) | 1999-12-15 |
| WO1991008770A1 (en) | 1991-06-27 |
| JPH05501543A (ja) | 1993-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68928946D1 (de) | Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper | |
| DE68925974T2 (de) | Konjugate zur steigerung der durchlässigkeit der gefässe | |
| DK0433088T3 (da) | Monoklonale antistoffer, der reagerer med et humant atheromaassocieret antigen | |
| EA200001169A1 (ru) | Специфично связывающиеся молекулы для сцинтиграфии, содержащие их конъюгаты и терапевтический способ лечения ангиогенеза | |
| PT627940E (pt) | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados | |
| ATE101202T1 (de) | Antikoerper. | |
| ATE89746T1 (de) | Polyspezifische anti-leukocytenkonjugat zum aufspueren und behandeln infektioeser und entzuendlicher laesionen. | |
| EP0671920A4 (de) | Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten. | |
| DE3781946D1 (de) | Therapeutische oder radiodiagnostische substanz. | |
| WO2000052054A3 (en) | Antibodies for cancer therapy and diagnosis | |
| DE69531613D1 (de) | Einführung einer thiol-gruppe in proteine für die radioimmundetektion und radioimmuntherapie auf der basis von radionukliden | |
| DE3682780D1 (de) | Mittel fuer die diagnose, die abbildung, die lokalisierung oder die behandlung von tumoren. | |
| DE3685625D1 (de) | Antikoerperkomplexe von haptenmodifizierten diagnostischen oder therapeutischen mitteln. | |
| DE3484198D1 (de) | Verfahren zur erhoehung der zielspezifizitaet in antikoerperbestimmungen und zur raeumung von nichtzielspezifischen diagnostischen und therapeutischen faktoren. | |
| DE69333076D1 (de) | Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis | |
| Clagett et al. | Insoluble immune complexes and chronic periodontal diseases in man and the dog | |
| DK172686A (da) | Antigen opnaaet ud fra humant vaev, fremgangsmaade til under anvendelse af antigenet at fremstille monoklonale antistoffer til diagnose og behandling af cancer, fremgangsmaade til paavisning af cancer, samt antistoffer mod antigenet | |
| EP1532162A4 (de) | Humanisierter anti-tag-72 cc49 zur diagnose und therapie humaner tumore | |
| IT1284076B1 (it) | Frammenti f(ab')2 e relative immunoglobuline igg, attivi come anticorpi specifici verso farmaci e i loro metaboliti, e loro | |
| IL95457A (en) | Preparations containing immunoconjugates for detection and treatment of infections | |
| DE69002769D1 (de) | Mittel zum nachweis einer fibrinolytischen wirkung. | |
| GB2314334A (en) | Improved production of antibodies through the use of antigen antibody complexes | |
| DE59712247D1 (de) | Mammakarzinom-assoziiertes gen | |
| FR2311844A1 (fr) | Preparation d'anticorps, antigene et procede pour le diagnostic de l'embolie pulmonaire | |
| ATE84069T1 (de) | Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |